Selected research
Market Structure
Global Diabetic Therapeutic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Diabetic Therapeutic Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Diabetic Therapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Diabetic Therapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Diabetic Therapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Diabetic Therapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Diabetic Therapeutic Drugs include Arbutus Biopharma, AstraZeneca, Belrose Pharma, Dong-A ST, Eisai, F. Hoffmann-La Roche, Mitsubishi Tanabe Pharma, Novo Nordisk and Perle Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Diabetic Therapeutic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Diabetic Therapeutic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Diabetic Therapeutic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diabetic Therapeutic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Diabetic Therapeutic Drugs Segment by Company
Arbutus Biopharma
AstraZeneca
Belrose Pharma
Dong-A ST
Eisai
F. Hoffmann-La Roche
Mitsubishi Tanabe Pharma
Novo Nordisk
Perle Biosciences
Sun Pharma
Pfizer
Eli Lilly
Merck
Novartis
Sanofi
Takeda Pharmaceuticals
Diabetic Therapeutic Drugs Segment by Type
Insulin Therapies
Non-Insulin Therapies
Diabetic Therapeutic Drugs Segment by Application
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Diabetic Therapeutic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Therapeutic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetic Therapeutic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Therapeutic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Diabetic Therapeutic Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Therapeutic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Diabetic Therapeutic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Diabetic Therapeutic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Insulin Therapies
- Non-Insulin Therapies
Applications
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
Companies covered
- Arbutus Biopharma
- AstraZeneca
- Belrose Pharma
- Dong-A ST
- Eisai
- F. Hoffmann-La Roche
- Mitsubishi Tanabe Pharma
- Novo Nordisk
- Perle Biosciences
- Sun Pharma
- Pfizer
- Eli Lilly
- Merck
- Novartis
- Sanofi
- Takeda Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Diabetic Therapeutic Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Diabetic Therapeutic Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Diabetic Therapeutic Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Diabetic Therapeutic Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Diabetic Therapeutic Drugs Market Dynamics
- 2.1 Diabetic Therapeutic Drugs Industry Trends
- 2.2 Diabetic Therapeutic Drugs Industry Drivers
- 2.3 Diabetic Therapeutic Drugs Industry Opportunities and Challenges
- 2.4 Diabetic Therapeutic Drugs Industry Restraints
3 Diabetic Therapeutic Drugs Market by Manufacturers
- 3.1 Global Diabetic Therapeutic Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Diabetic Therapeutic Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Diabetic Therapeutic Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Diabetic Therapeutic Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Diabetic Therapeutic Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Diabetic Therapeutic Drugs Manufacturers, Product Type & Application
- 3.7 Global Diabetic Therapeutic Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Diabetic Therapeutic Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Diabetic Therapeutic Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Diabetic Therapeutic Drugs Tier 1, Tier 2, and Tier 3
4 Diabetic Therapeutic Drugs Market by Type
- 4.1 Diabetic Therapeutic Drugs Type Introduction
- 4.1.1 Insulin Therapies
- 4.1.2 Non-Insulin Therapies
- 4.2 Global Diabetic Therapeutic Drugs Sales by Type
- 4.2.1 Global Diabetic Therapeutic Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Diabetic Therapeutic Drugs Sales by Type (2021-2032)
- 4.2.3 Global Diabetic Therapeutic Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Diabetic Therapeutic Drugs Revenue by Type
- 4.3.1 Global Diabetic Therapeutic Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Diabetic Therapeutic Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Diabetic Therapeutic Drugs Revenue Market Share by Type (2021-2032)
5 Diabetic Therapeutic Drugs Market by Application
- 5.1 Diabetic Therapeutic Drugs Application Introduction
- 5.1.1 Type 1 Diabetes
- 5.1.2 Type 2 Diabetes
- 5.1.3 Gestational Diabetes
- 5.2 Global Diabetic Therapeutic Drugs Sales by Application
- 5.2.1 Global Diabetic Therapeutic Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Diabetic Therapeutic Drugs Sales by Application (2021-2032)
- 5.2.3 Global Diabetic Therapeutic Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Diabetic Therapeutic Drugs Revenue by Application
- 5.3.1 Global Diabetic Therapeutic Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Diabetic Therapeutic Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Diabetic Therapeutic Drugs Revenue Market Share by Application (2021-2032)
6 Global Diabetic Therapeutic Drugs Sales by Region
- 6.1 Global Diabetic Therapeutic Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Diabetic Therapeutic Drugs Sales by Region (2021-2032)
- 6.2.1 Global Diabetic Therapeutic Drugs Sales by Region (2021-2026)
- 6.2.2 Global Diabetic Therapeutic Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Diabetic Therapeutic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Diabetic Therapeutic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Diabetic Therapeutic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Diabetic Therapeutic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Diabetic Therapeutic Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Diabetic Therapeutic Drugs Revenue by Region
- 7.1 Global Diabetic Therapeutic Drugs Revenue by Region
- 7.1.1 Global Diabetic Therapeutic Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Diabetic Therapeutic Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Diabetic Therapeutic Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Diabetic Therapeutic Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Diabetic Therapeutic Drugs Revenue (2021-2032)
- 7.2.2 North America Diabetic Therapeutic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Diabetic Therapeutic Drugs Revenue (2021-2032)
- 7.3.2 Europe Diabetic Therapeutic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Diabetic Therapeutic Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Diabetic Therapeutic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Diabetic Therapeutic Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Diabetic Therapeutic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Arbutus Biopharma
- 8.1.1 Arbutus Biopharma Company Information
- 8.1.2 Arbutus Biopharma Business Overview
- 8.1.3 Arbutus Biopharma Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Arbutus Biopharma Diabetic Therapeutic Drugs Product Portfolio
- 8.1.5 Arbutus Biopharma Recent Developments
- 8.2 AstraZeneca
- 8.2.1 AstraZeneca Company Information
- 8.2.2 AstraZeneca Business Overview
- 8.2.3 AstraZeneca Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 AstraZeneca Diabetic Therapeutic Drugs Product Portfolio
- 8.2.5 AstraZeneca Recent Developments
- 8.3 Belrose Pharma
- 8.3.1 Belrose Pharma Company Information
- 8.3.2 Belrose Pharma Business Overview
- 8.3.3 Belrose Pharma Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Belrose Pharma Diabetic Therapeutic Drugs Product Portfolio
- 8.3.5 Belrose Pharma Recent Developments
- 8.4 Dong-A ST
- 8.4.1 Dong-A ST Company Information
- 8.4.2 Dong-A ST Business Overview
- 8.4.3 Dong-A ST Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Dong-A ST Diabetic Therapeutic Drugs Product Portfolio
- 8.4.5 Dong-A ST Recent Developments
- 8.5 Eisai
- 8.5.1 Eisai Company Information
- 8.5.2 Eisai Business Overview
- 8.5.3 Eisai Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Eisai Diabetic Therapeutic Drugs Product Portfolio
- 8.5.5 Eisai Recent Developments
- 8.6 F. Hoffmann-La Roche
- 8.6.1 F. Hoffmann-La Roche Company Information
- 8.6.2 F. Hoffmann-La Roche Business Overview
- 8.6.3 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Product Portfolio
- 8.6.5 F. Hoffmann-La Roche Recent Developments
- 8.7 Mitsubishi Tanabe Pharma
- 8.7.1 Mitsubishi Tanabe Pharma Company Information
- 8.7.2 Mitsubishi Tanabe Pharma Business Overview
- 8.7.3 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Product Portfolio
- 8.7.5 Mitsubishi Tanabe Pharma Recent Developments
- 8.8 Novo Nordisk
- 8.8.1 Novo Nordisk Company Information
- 8.8.2 Novo Nordisk Business Overview
- 8.8.3 Novo Nordisk Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Novo Nordisk Diabetic Therapeutic Drugs Product Portfolio
- 8.8.5 Novo Nordisk Recent Developments
- 8.9 Perle Biosciences
- 8.9.1 Perle Biosciences Company Information
- 8.9.2 Perle Biosciences Business Overview
- 8.9.3 Perle Biosciences Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Perle Biosciences Diabetic Therapeutic Drugs Product Portfolio
- 8.9.5 Perle Biosciences Recent Developments
- 8.10 Sun Pharma
- 8.10.1 Sun Pharma Company Information
- 8.10.2 Sun Pharma Business Overview
- 8.10.3 Sun Pharma Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Sun Pharma Diabetic Therapeutic Drugs Product Portfolio
- 8.10.5 Sun Pharma Recent Developments
- 8.11 Pfizer
- 8.11.1 Pfizer Company Information
- 8.11.2 Pfizer Business Overview
- 8.11.3 Pfizer Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Pfizer Diabetic Therapeutic Drugs Product Portfolio
- 8.11.5 Pfizer Recent Developments
- 8.12 Eli Lilly
- 8.12.1 Eli Lilly Company Information
- 8.12.2 Eli Lilly Business Overview
- 8.12.3 Eli Lilly Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Eli Lilly Diabetic Therapeutic Drugs Product Portfolio
- 8.12.5 Eli Lilly Recent Developments
- 8.13 Merck
- 8.13.1 Merck Company Information
- 8.13.2 Merck Business Overview
- 8.13.3 Merck Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Merck Diabetic Therapeutic Drugs Product Portfolio
- 8.13.5 Merck Recent Developments
- 8.14 Novartis
- 8.14.1 Novartis Company Information
- 8.14.2 Novartis Business Overview
- 8.14.3 Novartis Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Novartis Diabetic Therapeutic Drugs Product Portfolio
- 8.14.5 Novartis Recent Developments
- 8.15 Sanofi
- 8.15.1 Sanofi Company Information
- 8.15.2 Sanofi Business Overview
- 8.15.3 Sanofi Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Sanofi Diabetic Therapeutic Drugs Product Portfolio
- 8.15.5 Sanofi Recent Developments
- 8.16 Takeda Pharmaceuticals
- 8.16.1 Takeda Pharmaceuticals Company Information
- 8.16.2 Takeda Pharmaceuticals Business Overview
- 8.16.3 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Product Portfolio
- 8.16.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Diabetic Therapeutic Drugs Value Chain Analysis
- 9.1.1 Diabetic Therapeutic Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Diabetic Therapeutic Drugs Production Mode & Process
- 9.2 Diabetic Therapeutic Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Diabetic Therapeutic Drugs Distributors
- 9.2.3 Diabetic Therapeutic Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst